Evidence map›Paper›PMID 28442017›Full record

ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2017

[Application of Bevacizumab in Non-small Cell Lung Cancer].

Ping Xu, Hongmei Li

Abstract readReview
In one paragraph

Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ping XuDepartment of Oncology, Affiliated Hospital of Qingdao University, Qingdao 266000, China.
Hongmei LiDepartment of Oncology, Affiliated Hospital of Qingdao University, Qingdao 266000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

At present, non-small cell lung cancer is one of the highest incidence of cancers in the world, and its incidence increased year by year, this situation prompted people to continue to seek a variety of treatment in order to extend the survival of patients and improve the quality of life of patients. This review aims to discuss the progress of bevacizumab in the treatment of non-small cell lung cancer, through the clinical data so far to explore the clinical use of the drug, the choice of patients and the future direction of development.

Indexed as

Angiogenesis InhibitorsBevacizumabCarcinoma, Non-Small-Cell LungHumansLung NeoplasmsQuality of LifeAngiogenesis InhibitorsBevacizumab

Identifiers

PMID28442017
PMCPMC5999671

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.